《组蛋白去乙酰化酶抑制剂chidamide治疗多发性骨髓瘤溶骨性病变的机制研究》解读

陈青骁; 蔡真

doi:10.13201/j.issn.1004-2806.2019.07.004

《组蛋白去乙酰化酶抑制剂chidamide治疗多发性骨髓瘤溶骨性病变的机制研究》解读

陈青骁,
蔡真^,

- 浙江大学医学院附属第一医院血液科骨髓移植中心多发性骨髓瘤治疗中心(杭州, 310003)
基金项目:
国家自然科学基金面上项目（No：81872322）

详细信息

通讯作者: 蔡真,E-mail:caiz@zju.edu.cn

中图分类号: R733.3

收稿日期: 2019-05-18

Comments on “Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease”

CHEN Qingxiao,
CAI Zhen^,

More Information

Corresponding author: CAI Zhen, E-mail: caiz@zju.edu.cn

Received Date: 18 May 2019

摘要

- HDAC抑制剂 /
- 多发性骨髓瘤 /
- MM溶骨病变 /
- 破骨细胞
- HDAC inhibitor /
- multiple myeloma /
- myeloma lytic bone disease /
- osteoclast

HTML全文

参考文献(19)

[1]	Fairfield H, Falank C, Avery L, et al.Multiple myeloma in the marrow:pathogenesis and treatments[J].Ann N Y Acad Sci, 2016, 1364:32-51.
[2]	Palumbo A, Anderson K.Multiple myeloma[J].N Engl J Med, 2011, 364:1046-1060.
[3]	Panaroni C, Yee AJ, Raje NS.Myeloma and bone disease[J].Curr Osteoporos Rep, 2017, 15:483-498.
[4]	Li Y, Zheng Y, Li T, et al.Chemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation, and polarization in multiple myeloma[J].Oncotarget, 2015, 6:24218-24229.
[5]	Roodman GD.Pathogenesis of myeloma bone disease[J].Leukemia, 2009, 23:435-441.
[6]	An G, Acharya C, Feng X, et al.Osteoclasts promote immune suppressive microenvironment in multiple myeloma:therapeutic implication[J].Blood, 2016, 128:1590-603.
[7]	Reagan MR, Liaw L, Rosen CJ, et al.Dynamic interplay between bone and multiple myeloma:emerging roles of the osteoblast[J].Bone, 2015, 75:161-169.
[8]	Seto E, Yoshida M.Erasers of histone acetylation:the histone deacetylase enzymes[J].Cold Spring Harb Perspect Biol, 2014, 6:a018713.
[9]	Harada T, Ohguchi H, Grondin Y, et al.HDAC3 regulates DNMT1 expression in multiple myeloma:therapeutic implications[J].Leukemia, 2017, 31:2670-2677.
[10]	Dou C, Li N, Ding N, et al.HDAC2 regulates FoxO1 during RANKL-induced osteoclastogenesis[J].Am J Physiol Cell Physiol, 2016, 310:C780-C787.
[11]	Cantley MD, Fairlie DP, Bartold PM, et al.Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro[J].J Cell Physiol, 2011, 226:3233-3241.
[12]	Santo L, Hideshima T, Kung AL, et al.Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma[J].Blood, 2012, 119:2579-2589.
[13]	Mishima Y, Santo L, Eda H, et al.Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death[J].Br J Haematol, 2015, 169:423-434.
[14]	San-Miguel JF, Einsele H, Moreau P.The role of panobinostat plus bortezomib and dexamethasone in treating relapsed or relapsed and refractory multiple myeloma:a European perspective[J].Adv Ther, 2016, 33:1896-1920.
[15]	Shi Y, Jia B, Xu W, et al.Chidamide in relapsed or refractory peripheral T cell lymphoma:a multicenter real-world study in China[J].J Hematol Oncol, 2017, 10:69.
[16]	Gong K, Xie J, Yi H, et al.CS055(Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells[J].Biochem J, 2012, 443:735-746.
[17]	Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, et al.Pathogenesis of bone disease in multiple myeloma:from bench to bedside[J].Blood Cancer J, 2018, 8:7.
[18]	Bringhen S, De Wit E, Dimopoulos MA.New agents in multiple myeloma:an examination of safety profiles[J].Clin Lymphoma Myeloma Leuk, 2017, 17:391-407.
[19]	Pavithra L, Mukherjee S, Sreenath K, et al.SMAR1 forms a ternary complex with p53-MDM2 and negatively regulates p53-mediated transcription[J].J Mol Biol, 2009, 388:691-702.